Pharmafile Logo

BenevolentAI

- PMLiVE

Pharma-Exclusive Webinar: Redefining Engagement in the AI Era

Join Impetus Digital's pharma-exclusive webinar to discover how compliant AI tools and virtual workflows can elevate static programs into high-retention, interactive experiences without enterprise overhead.

Impetus Digital

- PMLiVE

NEW PHARMA-EXCLUSIVE WEBINAR: Beyond the Hype; Practical, Compliant AI Solutions for Pharma Engagement

See how top-tier pharma teams use compliant AI tools and virtual QIPs to capture real-time market intelligence, confidence scores, and audience insights from live dashboards

Impetus Digital

- PMLiVE

US FDA accepts supplemental Biologics License Application for Merck’s Enflonsia

The treatment is to protect children under two years of age from respiratory syncytial virus

- PMLiVE

Permission to pause: making treatment breaks part of the cancer care conversation

Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.

Cuttsy + Cuttsy

- PMLiVE

Key takeaways from ASCO® 2026

Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year's congress revealed for pharmaceutical organisations. Together, they...

Inizio

- PMLiVE

Webcast | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026

Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.

Inizio

- PMLiVE

Pfizer and Innovent Biologics agree on deal worth up to $10.5bn

The companies plan to research and develop 12 new cancer treatments

- PMLiVE

One-carbon Therapeutics collaborates with Tempus in cancer treatment

The treatment is currently being evaluated in a phase 1/2 multicentre clinical study

- PMLiVE

Gilead to acquire Tubulis for up to $5bn

The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need

- PMLiVE

Merck agrees on $2.2bn deal with Quotient Therapeutics to develop IBD treatment

Quotient’s somatic genomics platform technology will be used to develop the treatment

- PMLiVE

HRW Wins 2026 Artificial Intelligence Excellence Award in the Pharmaceutical Category

Healthcare Research Worldwide (HRW) has been named a winner in the 2026 Artificial Intelligence Excellence Awards in the Pharmaceutical category, recognizing its innovative use of AI to deliver real-world impact....

Healthcare Research Worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links